All information provided herein is for informational purposes only and should not be deemed as a recommendation to buy or sell any security mentioned. Pershing Square Capital Management, L.P. (“Pershing Square”) believes this presentation contains a balanced presentation of the performance of the portfolios it manages, including a general summary of certain portfolio holdings that have both over and under performed our expectations.

This presentation contains information and analyses relating to all of the publicly disclosed positions over 50 basis points in the portfolio of Pershing Square Holdings, Ltd. (“PSH” or the “Company”) during 2015. Pershing Square may currently or in the future buy, sell, cover or otherwise change the form of its investments discussed in this presentation for any reason. Pershing Square hereby disclaims any duty to provide any updates or changes to the information contained herein including, without limitation, the manner or type of any Pershing Square investment.

Past performance is not necessarily indicative of future results. All investments involve risk including the loss of principal. It should not be assumed that any of the transactions or investments discussed herein were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the investments discussed herein. Specific companies or investments shown in this presentation are meant to demonstrate Pershing Square’s active investment style and the types of industries and instruments in which we invest and are not selected based on past performance.

The analyses and conclusions of Pershing Square contained in this presentation are based on publicly available information. Pershing Square recognizes that there may be confidential or otherwise non-public information in the possession of the companies discussed in the presentation and others that could lead these companies to disagree with Pershing Square’s conclusions. The analyses provided include certain statements, assumptions, estimates and projections prepared with respect to, among other things, the historical and anticipated operating performance of the companies. Such statements, assumptions, estimates, and projections reflect various assumptions by Pershing Square concerning anticipated results that are inherently subject to significant economic, competitive, legal, regulatory, and other uncertainties and contingencies and have been included solely for illustrative purposes. No representations, express or implied, are made as to the accuracy or completeness of such statements, assumptions, estimates or projections or with respect to any other materials herein. See also “Forward-Looking Statements” in Additional Disclaimers and Notes to Performance Results at the end of this presentation. All trademarks included in this presentation are the property of their respective owners.

This document may not be distributed without the express written consent of Pershing Square and does not constitute an offer to sell or the solicitation of an offer to purchase any security or investment product. This presentation is expressly qualified in its entirety by reference to PSH’s prospectus which includes discussions of certain specific risk factors, tax considerations, fees and other matters, and its other governing documents.

SEE ADDITIONAL DISCLAIMERS AND NOTES TO PERFORMANCE RESULTS AT THE END OF THIS PRESENTATION FOR ADDITIONAL IMPORTANT INFORMATION
## Table of Contents

- 2015 Performance Review
- Bond Offering
- Current Portfolio Update
- Business & Organizational Update
2015 Performance Review
# Pershing Square Holdings, Ltd. Performance

<table>
<thead>
<tr>
<th>Year</th>
<th>Net Returns</th>
<th>S&amp;P 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>-20.5%</td>
<td>1.4%</td>
</tr>
<tr>
<td>2014</td>
<td>40.4%</td>
<td>13.7%</td>
</tr>
<tr>
<td>2013</td>
<td>9.6%</td>
<td>32.4%</td>
</tr>
</tbody>
</table>

Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. Please see the additional disclaimers and notes to performance results at the end of this presentation.
Cumulative Net Returns Since Inception of Strategy (January 1, 2004)

Pershing Square, L.P. Net Returns vs. Indexes
through December 31, 2015

Pershing Square, L.P.: 567.1%
S&P 500: 135.3%

Performance is for Pershing Square, L.P., the Pershing Square fund with the longest track record. Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. Please see the additional disclaimers and notes to performance results at the end of this presentation.
Performance in Up & Down Markets

Pershing Square, L.P.
Net Returns vs. S&P 500 (1/1/2004 through 12/31/2015)

Performance is for PSLP the fund managed by Pershing Square with the longest track record. Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. Please see the additional disclaimers and notes to performance results at the end of this presentation.

(1) “Up” months and “down” months are defined as months in which the closing price of the S&P 500 on the last business day of the relevant month was higher and lower, respectively, than the closing price of the S&P 500 on the last business day of the immediately preceding month.
## 2015 Winners and Losers (gross returns)

**Winners**
- Allergan Inc: 3.9%
- Mondelez International: 3.3%
- Zoetis Inc: 1.2%
- All Other Positions: 0.3%

**Total:** 8.7%

**Losers**
- Valeant Pharmaceuticals: (11.4%)
- Herbalife: (3.9%)
- Canadian Pacific Railway: (3.8%)
- Platform Specialty Products: (2.8%)
- Actavis (AGN Short/Hedge): (1.9%)
- Howard Hughes Corp: (1.3%)
- Air Products & Chemicals Inc: (1.2%)
- All Other Positions: (1.7%)

**Total:** (28.0%)

Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. Each position contributing or detracting 50 basis points or more from returns when rounded to the nearest tenth is shown separately. Positions contributing or detracting less than 50 basis points are aggregated. The returns (and attributions) set forth above do not reflect certain fund expenses (e.g., administrative expenses). Please see the additional disclaimers and notes to performance results at the end of this presentation.
Long and Short Attribution (Gross Returns)

<table>
<thead>
<tr>
<th>Year</th>
<th>Long</th>
<th>Short/Hedge</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>61.6%</td>
<td>(5.9%)</td>
</tr>
<tr>
<td>2005</td>
<td>53.7%</td>
<td>(1.6%)</td>
</tr>
<tr>
<td>2006</td>
<td>36.9%</td>
<td>(6.9%)</td>
</tr>
<tr>
<td>2007</td>
<td>(5.6%)</td>
<td>34.9%</td>
</tr>
<tr>
<td>2008</td>
<td>(23.2%)</td>
<td>11.6%</td>
</tr>
<tr>
<td>2009</td>
<td>60.5%</td>
<td>(11.4%)</td>
</tr>
<tr>
<td>2010</td>
<td>43.8%</td>
<td>(4.7%)</td>
</tr>
<tr>
<td>2011</td>
<td>2.5%</td>
<td>(2.1%)</td>
</tr>
<tr>
<td>2012</td>
<td>16.9%</td>
<td>1.1%</td>
</tr>
<tr>
<td>2013</td>
<td>25.8%</td>
<td>(12.0%)</td>
</tr>
<tr>
<td>2014</td>
<td>42.4%</td>
<td>5.8%</td>
</tr>
<tr>
<td>2015</td>
<td>(9.3%)</td>
<td>(5.6%)</td>
</tr>
</tbody>
</table>

HKD call options are included in short attributions from 2011 through 2014 and are included in long attribution for 2015.

Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. Please see the additional disclaimers and notes to performance results at the end of this presentation.
### Total Assets Under Management

**$ in millions**

<table>
<thead>
<tr>
<th>Fund/Co-investment</th>
<th>12/31/2015 AUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pershing Square, L.P.</td>
<td>$4,242</td>
</tr>
<tr>
<td>Pershing Square International, Ltd.</td>
<td>$4,705</td>
</tr>
<tr>
<td>Pershing Square Holdings, Ltd.</td>
<td>$5,217</td>
</tr>
<tr>
<td>Pershing Square II, L.P.</td>
<td>$106</td>
</tr>
<tr>
<td>Pershing Square V Funds (Air Products)</td>
<td>$487</td>
</tr>
<tr>
<td><strong>Total Core Fund AUM</strong></td>
<td><strong>$14,270</strong></td>
</tr>
<tr>
<td><strong>Total Firm AUM</strong></td>
<td><strong>$14,757</strong></td>
</tr>
</tbody>
</table>

Assets under management are net of any capital redemptions (including crystallized performance fee/allocation, if any). No deductions are made for any capital redemptions if such redemption amounts are to be immediately re-subscribed into the same Pershing Square fund. Pershing Square L.P., Pershing Square International, Ltd. and Pershing Square Holdings, Ltd. have investments totaling $258m, $167m, and $82m, respectively, in PS V, L.P. or PS V International, Ltd., co-investment vehicles formed to invest in the securities of (or otherwise seek to be exposed to the value of securities issued by) Air Products and Chemicals, Inc. (together “PSV” or “Pershing Square V Funds”), as of December 31, 2015. These investment amounts are represented in Total Core Fund AUM and only once in Total Firm AUM.
Bond Offering
PSH Bond Offering Summary

PSH issued $1B 7-year senior unsecured notes on June 26, 2015

- Maturity: 07/15/2022
- Coupon: 5.500%
  - Payable semi-annually on January 15 and July 15
- Ratings: BBB (negative outlook) / BBB+ (S&P / Fitch)
- Over 90 investors participated in the offering
- No NAV maintenance covenants
“Permanent” capital\(^{(1)}\) represents nearly half of our assets.

(1) “Permanent” capital represents GP and affiliates, deferred incentive fees, PSH NAV, and PSH bond.
(2) The deferred incentive fees are due to expire on January 1, 2017.
(3) The bonds are due July 15, 2022.
Discount to NAV has Narrowed Since Inception
Current Portfolio Update
Principal Mistakes We Made in 2015

- We relied too much on “platform value”

- We missed opportunities to trim or exit holdings

- We did not sufficiently discount regulatory risk and political sensitivity

A year when many lessons were learned, 2015 was also an important reminder that stocks can trade at any price in the short term...

(1) Reflects average cost at announcement date
Despite our missteps, we believe our portfolio holdings today trade at a substantial discount to intrinsic value partially because of certain unique market dislocations.

✓ Concerns regarding oil prices and China’s economy have significantly impacted the market prices of many of our investments, despite their limited exposure to these risks.

✓ Pershing Square “followers” are liquidating funds creating intense selling pressure on our investments with strong “follower” ownership.

✓ Huge capital inflows into index funds have created support for indexed constituent company valuations.

- Most of our long positions (representing 54% of our portfolio) are not components of major market indices.

Other Factors Also Contributed to Poor Results
While We Wait for the Weighing Machine…

Over the long term, we believe that the market prices and intrinsic values of our investments will converge

✓ Permanency of our capital base will allow us to weather this volatility
✓ Our influence on our portfolio companies should allow us to continue to enhance the value of our investments

In the near term, new investment opportunities abound

✓ Recent market conditions have created new opportunities
✓ Many high quality businesses with catalysts to increase value are currently at or nearing attractive valuations

*We are unlikely to make wholesale changes in the short term to the current portfolio as we find our current investments attractive. That said, we would be surprised if we did not add at least one major new investment in the next few months.*
Mondelez International (MDLZ)

- One of the world’s largest snack companies with 2014 revenues of $30 billion\(^{(1)}\)
- ~$66bn equity market capitalization
- Born out of the breakup of Kraft Foods in 2012
- High quality, simple, predictable, free-cash-flow-generative business
- Only large, publicly traded, uncontrolled “pure-play” snacks company
- We currently own shares and derivatives representing a ~6.6% ownership stake in the company

\(^{(1)}\) 2014 revenues are pro forma for the coffee JV transaction closed on July 2, 2015 (the “Coffee JV”).
Mondelez: Fantastic Billion Dollar Brands

Mondelez has the most attractive stable of sweet snack brands of any packaged food company

Mondelez Billion-Dollar Brands

Source: Public filings.
(1) Owned by the Coffee JV between Mondelez and D.E. Master Blenders.
Snacks is One of the Best Food Categories

**Strong global growth and scale**
- $1.2 trillion global market with historical growth of 6% per annum\(^{(1)}\)
- Tremendous future growth opportunity in emerging markets
- Category responds well to advertising and in-store merchandising

**High category margins**
- Low private-label penetration
- Strong sales in highly profitable immediate consumption channels

**Secular winner in global packaged foods**
- Well-aligned with consumer trends of eating more frequent, smaller meals and convenience
- “Small treats” significantly better positioned than processed meals and other center store products

---

\(^{(1)}\) Source: Mondelez February 2015 CAGNY conference transcript.
Mondelez EBIT Margins vs. Peers

Source: Capital IQ, public filings, Pershing Square estimates.
Note: Represents calendar year 2015 Capital IQ consensus estimates for all companies except Mondelez which is based on 2015 guidance excluding 20-30bps of stranded overhead costs from the divestiture of their coffee business and Unilever which has already reported full year 2015 results. Kraft Heinz margin is pro forma for $1.5 billion of announced cost savings and merger synergies. Unilever margin is for the Food and Refreshment business only and excludes 50bps of assumed restructuring charges.
Mondelez is Effectively a New Company

We believe MDLZ’s enormous efficiency opportunity exists because it was created through a series of acquisitions made by legacy Kraft that were never properly optimized or integrated.

Acquisitions drove supply chain complexity

- Significant number of SKUs, formats and formulas
- Fragmented supplier base
- Sub-scale plants with low efficiency assets

Source: Mondelez February 2015 CAGNY conference presentation.
Mondelez Zero-Based Budgeting (ZBB)

While management has embraced ZBB to address their high G&A, Mondelez’s version of ZBB is much less robust than the 3G approach.

**EBIT Margin Comparison**

<table>
<thead>
<tr>
<th></th>
<th>2007 Reported</th>
<th>2007 PF</th>
<th>2014 Reported</th>
<th>2016 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014 EBIT</td>
<td>15%</td>
<td>17%</td>
<td>12%</td>
<td>15-16%</td>
</tr>
<tr>
<td>Margin (%)</td>
<td>+900 bps in ~2 years</td>
<td>+1,300 bps in ~3 years</td>
<td>+300 - 400 bps in ~2 years</td>
<td></td>
</tr>
</tbody>
</table>

Source: Public filings, Pershing Square estimates.

(1) Excludes accelerated depreciation for restructuring and deal-related amortization generated by 3G’s acquisition of Heinz.
(2) Represents Anheuser-Busch 2007 EBIT plus 100% of announced cost synergies of $2.25bn from its acquisition by InBev. The acquisition closed in November 2008 and all cost synergies were achieved by the end of 2011.
(3) 2014 EBIT margin is pro forma for the Coffee JV.
Mondelez has invested ~$1.5 billion to upgrade its manufacturing base, which should expand gross margins by ~250 bps by 2018

- We are looking forward to a significant gross margin increase as the new Salinas, Mexico facility ramps up
- We believe the potential for long-term gross margin expansion is strong

<table>
<thead>
<tr>
<th>Gross Margin Impact of Advantaged Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of Power Brands on Advantaged Assets - 2018</td>
</tr>
<tr>
<td>% of Power Brands on Advantaged Assets - Current</td>
</tr>
<tr>
<td>Power Brands as % of Total Sales in 2018</td>
</tr>
<tr>
<td>% of Sales Moved to Advantaged Assets</td>
</tr>
<tr>
<td>Advantaged Assets Margin Uplift&lt;sup&gt;(1)&lt;/sup&gt;</td>
</tr>
<tr>
<td>Margin Increase from Move to Advantaged Assets</td>
</tr>
</tbody>
</table>

Source: Management commentary, Pershing Square estimates.

<sup>(1)</sup> Based on management commentary during 2015 Back to School breakout session that advantaged assets provide a gross margin uplift of between 400-1,000bps.
Case Study: Heinz Gross Margins Under 3G

Under 3G management, Heinz expanded global gross margins by ~600 bps and Europe gross margins by ~1,100 bps in just two years without a material additional capital investment.

Source: Heinz and Kraft Heinz public filings. Q2’13 used as starting point since 3G acquisition of Heinz closed on June 7, 2013. Q2’15 used as end point since it is the last quarter before Heinz merged with Kraft on July 2, 2015.
Mondelez can dramatically improve its profitability using the same tools used by 3G

- **Net revenue management**
  - Elimination of unproductive trade spend, particularly in Europe
  - Reduction in global SKU count from ~74,000 in 2014

- **Procurement Productivity**
  - Consolidation of suppliers from ~100,000 in 2013

- **SG&A rationalization**
  - Implementation of zero-based budgeting across the organization
  - Creation of an “ownership culture” through appropriate incentives
While management’s plan to increase margins to 15-16% by 2016 is a step in the right direction, we believe optimized margins are far higher.

**Mondelez EBIT Margin**

Source: Mondelez public filings, Pershing Square estimates. 2014 is pro forma for the Coffee JV. 2015 excludes stranded overhead costs from the Coffee JV.
## Mondelez is an Excellent Merger Candidate

<table>
<thead>
<tr>
<th></th>
<th>Advantaged Categories</th>
<th>Growth Potential</th>
<th>Savings Opportunity</th>
<th>Change-of-Control Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mondelēz International</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
</tr>
<tr>
<td><strong>General Mills</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
</tr>
<tr>
<td><strong>Kellogg’s</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
</tr>
<tr>
<td><strong>Campbell’s</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
</tr>
<tr>
<td><strong>HERSEY’S</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
</tr>
<tr>
<td><strong>SMUCKERS</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ (1)</td>
</tr>
<tr>
<td><strong>McCormick</strong></td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️</td>
<td>✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ ✔️ (2)</td>
</tr>
</tbody>
</table>

(1) 10:1 voting ratio applies for shares held for at least four years. Company is still managed by the founding family.
(2) Voting stock represents 9.3% of total shares outstanding and is held largely by an employee 401(k) plan and current and former employees.
MDLZ stock increased 15% from our average cost to YE 2015, and 7% to January 22, 2016

Note: The performance of Mondelez's share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
Valeant Pharmaceuticals International (VRX)

- Multinational pharmaceutical and medical device company
  - >$12bn 2016 estimated sales
  - ~21,000 employees
  - Market leadership in dermatology, gastroenterology, ophthalmology, and consumer health products

- In 2008, new management implemented an unconventional business model that has historically created large amount of shareholder value
  - Innovative marketing, management, and R&D strategies designed to avoid waste and maximize return on capital
  - Acquisitions of assets in attractive categories
  - Valeant is adapting its model in response to recent criticism

- Pershing Square's history with Valeant
  - Pershing Square partners with Valeant in 2014 to acquire Allergan
  - On February 9, 2015, Pershing Square purchases first shares of Valeant at a price of $161
Valeant’s major franchises are underappreciated:

**Strong Growth Platforms**

<table>
<thead>
<tr>
<th>U.S. Gastrointestinal</th>
<th>U.S. Dermatology (1)</th>
<th>U.S. Ophthalmology and Eye Care (B+L)</th>
<th>U.S. Consumer</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCERIS</td>
<td>JUBLIA (juxtan ochia)</td>
<td>LOTEMAX.GEL</td>
<td></td>
</tr>
<tr>
<td>RELISOR</td>
<td>LUZU (lipocaine)</td>
<td>PROLENSA</td>
<td></td>
</tr>
<tr>
<td>apriso</td>
<td>ONEXTON (inivirus)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xifaxan</td>
<td>SOLODYN (iopamidol)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>~20%</td>
<td>~15%</td>
<td>~10%</td>
<td>~5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emerging markets (2)</th>
<th>Ex-U.S. developed markets (2)</th>
<th>U.S. Oncology, Dentistry, Women’s Health, Neuro/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Arestin (mioglycin H2 ting MICROSPHERES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PROVENGE (sipuleucel-T)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>addyi (filbanserin)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>~20%</td>
<td>~10%</td>
<td>~20%</td>
</tr>
</tbody>
</table>

(1) Including Solta and Obagi
(2) Including Ophthalmology, Dermatology, and GI sales

Chart from Valeant presentation 1/13/16
Valeant’s major franchises are underappreciated:

**Bausch & Lomb: ~30% of sales**

- Durable product portfolio
- 11% organic growth in 2014, ~6% growth through Q3 2015
- Growth drivers include favorable secular trends and strong product portfolio:
  - Increased prevalence of eye disease supports growth of surgical, drug, and consumer markets
  - Capacity expansion to accommodate strong demand for contact lens products
  - ~25% of sales are made in emerging markets
  - Late stage pipeline includes Vesneo, a potential $1bn new glaucoma drug
- Traded at an average of 20x Forward EPS as a public company

**Gastrointestinal (Salix): ~20% of sales**

- Strong collection of products treating patients with diseases such as:
  - Hepatic Encephalopathy, Ulcerative Colitis, Opioid Induced Constipation
- Xifaxan has nearly $1bn of annualized sales and recent volume growth of 25%+ Y/Y
- October Y/Y volume growth of other significant products: Apriso +8%, Uceris +30%, Relistor +33%
- Pipeline: Likely approval of Relistor Oral in 2016

---

Valeant’s major franchises and Walgreen’s partnership are underappreciated:

**US Dermatology: ~15% of sales**
- Largest portfolio of non-biologic medical dermatology products in the United States
- Prescribers often strongly prefer branded alternative to generics
- Retained ~80% of volume following Philidor disruption
- ~30% of Q3 2015 sales from four recently launched products
- Drug Pipeline: Seven Phase III or FDA Submitted, Eight Pre-Phase III Products

**Emerging Markets Branded Generics: ~10% of sales**
- Durable portfolio of branded generic products in growing markets
- Opportunity to grow existing drugs and launch new products

**Walgreen’s Partnership:**
- Will support growth of Rx Dermatology, Ophthalmology, and Off-Patent portfolio
- Benefits to patients and physicians: Convenient access, financial and administrative support, cash pay option
- Benefits to payors: $600mm of price cuts, transparency, no mail order

---

1Excludes estimated B&L Emerging Markets revenue.
Valeant: Share Price Performance

Valeant Share Price – 2/9/2015 to 1/22/2016

VRX stock has decreased 48% from our average cost to YE 2015, and 55% to January 22, 2016

Note: The performance of Valeant’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds. Source: Bloomberg.
Valeant: Recent Events

Valeant Share Price – 9/1/2015 to 10/29/2015

9/20/15: NYT article on price increases in pharma, with focus on Turing Pharmaceuticals after >5,000% drug price increase

9/21/15: Hillary Clinton tweets about pharma “price gouging”

9/28/15: House Dems request Republican chairman subpoena VRX regarding price increases; Senator McCaskill releases letter to VRX

10/14/15: Valeant discloses receipt of two Federal subpoenas regarding patient assistance programs among other topics

10/19/15: Valeant announces strong Q3 earnings but investors are confused by VRX's perceived “strategy shift”

10/14/15: Valeant responds to Senator McCaskill

Pershing Square’s Perspectives on Key Topics

A Price Increases
- Substantial majority of Valeant’s business units have volume growth
- Media reports are focused on gross prices; net realized prices to manufacturer are much lower
- Drugs improve health outcomes and can reduce overall cost of healthcare; returns on investment critical to drug innovation

B VRX’s Perceived “Strategy Shift”
- VRX’s strategy is multi-faceted, focused on creating shareholder value, adapts with opportunities:
  - M&A: No more “price increase” deals (only handful of ~150 historical acquisitions)
  - R&D: Increasing modestly to pursue attractive late-stage development opportunities

Note: The performance of Valeant’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

Source: Bloomberg.
Valeant: Recent Events (continued)

Valeant Share Price – 9/1/2015 to 10/29/2015

Pershing Square’s Perspectives on Key Topics

C  Citron Report
- Claim that VRX “stuffed the channel” and falsely recognized revenue is verifiably false
- Accounting for sales to Philidor is more conservative than accounting rules applied for sales made to “traditional” distributors

D  Specialty Pharmacies / Philidor
- Increasingly important distribution channel for the industry
- Specialty pharmacies improve patient and physician access to medications
- Lack of early disclosure and details regarding VRX’s relationship with Philidor created appearance of malfeasance

Note: The performance of Valeant’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds. Source: Bloomberg.
Valeant: Recent Events (continued)

Pershing Square's Perspectives on Key Topics

E  Valeant Investor Day
- 2016 EBITDA guidance in line with Pershing Square expectations
- Long-term partnership with Walgreens creates savings for healthcare system, convenience for patients, and profit opportunity for Valeant
- Management highlights quality of product portfolio, management team, and pipeline

F  Management
- If Pearson does not return as CEO, his strategic vision and operating talents will be missed
- We have a lot of confidence in Schiller, who worked closely with Pearson at Valeant following a 20+ career at Goldman Sachs
- Decentralized management structure has created a deep bench of talent at the company

Note: The performance of Valeant’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds. Source: Bloomberg.
Valeant shares trade at ~7x management’s ~$14 2016 EPS target (ex-one time items). We expect EPS to exceed $20 by 2020, excluding acquisitions.
Air Products (APD): Overview

- One of four global industrial gas companies
- Air Products’ business is diversified by geography, with modest exposure to emerging markets including China
  - U.S. / Canada 42%
  - Europe 24%
  - Asia, ex. China 16%
  - China 12%
  - SA 6%
- APD is diversified by supply mode, with significant exposure to the highest-quality on-site supply mode
  - On-site/Pipeline: 40%
    - 15-20 year contracts
    - Limited volume risk
    - Energy pass-through
  - Liquid Bulk: 21%
    - 3-5 year contracts
    - Local supply chain
  - Packaged Gas: 13%
    - Short-term contracts
    - Local supply chain
  - Equipment & Services: 6%
    - Sale of equipment
    - PO based
  - Materials Technologies (includes 3% Equipment): 20%
    - Differentiated positions
    - Low capital intensity
Air Products: Investment Thesis

- **High-quality, simple, predictable, free-cash-flow generative business**
  - Global oligopoly which enjoys attractive returns due to local incumbency advantages driven by utility-like contracts with large customers and the high transportation costs of distributing additional product to surrounding customers
  - Buffered from macro: diversified; contracted; low-cost, critical and consumable input
  - GAAP earnings meaningfully understate cash flow as the useful life of APD’s assets far exceeds GAAP depreciable life (which is set by initial contract length)

- **Substantial untapped potential, cheap “as-fixed”**
  - Decades of underperformance, but shortfalls were fixable
  - Historical 600 bps+ operating margin gap to comparable Praxair could be closed
  - Potential to substantially improve earnings in medium term; APD’s shares did not reflect this latent opportunity at the time of our purchases

New CEO Seifi Ghasemi has begun a transformation of Air Products, which we expect will continue to create meaningful value for shareholders
2015 was a year of substantial progress:

- Successfully restructured Air Products, creating a decentralized organization with greater accountability
- Took action to reduce corporate overhead costs by $300mm run-rate ($170mm realized in FY 2015)
- Operating margins improved 310 bps to 19%
- Significant capex brought on-stream and producing
- FY 2015 EPS of $6.57 up 14%, despite 7% foreign exchange headwind
  - Exceeded the high-end of initial guidance despite unforeseen macroeconomic and foreign exchange headwinds
- Announced significant high-quality project wins, which will fuel growth
- Announced spin-off of non-core materials technology business, Versum Materials, on or before September 2016

Source: Company Filings and Disclosures.
Air Products’ Upside Remains Significant

- Despite APD’s significant progress, recent macroeconomic concerns have caused APD’s stock to trade at what we believe to be a material discount to its intrinsic value.

- APD’s business remains resilient: diversified; contracted; low-cost, critical and consumable input.

- FY 2016 guidance calls for $7.25 to $7.50 of EPS (+10% to 14%)
  - Assumes no global growth and continued economic weakness.

- Catalysts for value creation are not dependent on macroeconomic strength.
  - Cost savings and efficiency:
    - Industrial gas margins of 18% still ~500 bps behind Praxair.
    - $430mm, or 72%, of total cost savings will be achieved in 2016 and beyond.
  - Significant capital expenditures brought on-stream.
  - Spin-off of Versum Materials will create two leading, pure-play companies.

APD is well on its way to achieving its goal of being the safest and most profitable industrial gas company in the world, which we believe will create significant value for shareholders.

Source: Company Filings and Disclosures.

46
The total return for APD shares was -8% in 2015

Stock price performance of APD from 1/1/2015 to 12/31/2015

1/29/15: FY Q1 results:
- EPS up 16%
- Reaffirms FY guidance despite f/x headwind of $0.25

4/30/15: FY Q2 results:
- Underlying revenue growth of 5%
- Operating margins up 340 bps to 18.3%
- EPS up 17%

7/30/15: FY Q3 results:
- Underlying revenue growth of 4%
- Operating margins up 380 bps to 19.5%
- EPS up 13%
- Raised, FY guidance, and provided four-year timeline for closing margin gap with PX

9/17/15: APD announces spinoff of Materials Technology business, to be named Versum Materials, on or before Sept 2016

10/29/15: FY Q4 and guidance:
- FY Q4: EPS up 10%
- FY 2015: EPS of $6.57 up 14%, despite 7% f/x headwind; operating margins up 380 bps to 19.5%
- FY '16 EPS guidance of $7.25 to $7.50, up 10 to 14%

Note: The performance of APD’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
APD stock increased 29% from our average cost to January 22, 2016

Stock price performance of APD from 5/22/2013 to 1/22/2016

- **7/25/13:** APD adopts Poison Pill
- **7/23/14:** Seifi hosts first earnings call, sole focus to create shareholder value
- **9/26/13:** APD announces agreement with Pershing Square:
  - Three Directors added to the board
  - CEO John McGlade to retire; CEO search commences
- **10/30/14:** APD announces record FY Q4 results
- **6/18/14:** APD’s Board names Seifi Ghasemi its Chairman, President, and CEO effective July 1st
- **10/29/15:** FY ‘15 and guidance:
  - FY 2015: EPS of $6.57 up 14%, despite $0.25 f/x headwind; operating margins up 380 bps to 19.5%
  - FY ‘16 EPS guidance of $7.25 to $7.50, up 10 to 14%
- **9/17/15:** APD announces spinoff of Versum Materials
- **7/31/13:** Pershing Square 13D Filed
- **10/29/15:** FY ‘15 and guidance:
  - FY 2015: EPS of $6.57 up 14%, despite $0.25 f/x headwind; operating margins up 380 bps to 19.5%
  - FY ‘16 EPS guidance of $7.25 to $7.50, up 10 to 14%

Note: The performance of APD’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

Source: Bloomberg.
Zoetis Inc.

- Split-off from Pfizer June 2013
- ~$22bn equity market capitalization
- Largest manufacturer of medication for pets and livestock in the world
- Only large, publicly traded “pure-play” animal health business
- Pershing Square began buying Zoetis shares on July 22nd 2014 and currently owns a 8.6% economic stake in the company
Zoetis Engagement

February 4th, 2015 Agreement

- **Board Composition**
  - On February 4th, 2015, Zoetis agreed to add Pershing Square investment team member Bill Doyle to the Zoetis board
  - Additionally, on April 13th, Zoetis and Pershing Square agreed to name Allergan Executive Chairman Paul Bisaro to the Zoetis board

Restructuring Programs

- **On November 18th, 2014,** several days after our investment, management hosted an investor day to detail the company’s organic revenue growth opportunity and its supply chain restructuring program
  - Announced goal to increase gross margins 200bps by 2020

- **On May 5th, 2015** Zoetis announced an additional restructuring program
  - Management expects this $300mm cost reduction program and continued operating leverage to increase operating margins from ~25% in 2014 to ~34% by 2017
Zoetis Engagement – Cost Structure Initiative

- Comprehensive initiative to simplify operations, improve cost structure, and better allocate resources to generate $300 million annual cost savings by 2017
  - Eliminate ~5,000 lower-revenue, lower-margin SKUs
  - Shift from direct sales representation to distribution in ~30 smaller markets
  - Consolidate from a four-region structure to a two-region structure
  - Significant reductions in corporate G&A
  - Smaller reductions in R&D to enhance focus
  - Program is incremental to previously announced Supply Network efficiency effort
Productive R&D and Business Development

- Zoetis maintains productive R&D and business development
  - Received USDA conditional license for IL-31 for atopic dermatitis (first-of-its-kind antibody therapy)
  - EU Approved Simparica, once monthly chewable treatment for canine fleas, ticks and sarcoptic mange
  - Completed acquisition of Abbott Animal Health
  - Completed Acquisition of PHARMAQ, the global leader in vaccines innovation for health products in aquaculture (fish farming)
Strong Operational Performance

- 2014 revenue: $4.8 bn; Adjusted Diluted EPS $1.57 per share

- 2015 guidance:
  - Revenue: $4.7 – 4.75 billion
  - Adjusted Diluted EPS: $1.70 – $1.74 per share (compared to original EPS guidance of $1.61 – $1.68 provided in November 2014)

- In 2015, held then increased adjusted net income per share guidance in the face of FX and Venezuela headwinds that decreased revenue expectations by ~550 bps
The total return for Zoetis shares was 12% in 2015

Note: The performance of Zoetis's share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

Source: Capital IQ.
ZTS stock increased 19% from our average cost to January 22, 2016
CP’s business is diversified by freight and destination:

**Freight Mix (% of ‘15 Rev.)**
- US Grain, 8%
- Canadian Grain, 15%
- Coal, 10%
- Potash, 6%
- Fertilizer & Sulphur, 4%
- Chems & Plastics, 10%
- Metals, Minerals, Cons. Products, 10%
- Crude, 6%
- Automotive, 5%
- Forest Products, 4%
- Domestic Intermodal, 11%
- International Intermodal, 9%

**Destination Mix (% of ‘14 Rev.)**
- U.S., 17%
- Canada, 17%
- Cross-Border, 31%
- Global, 35%

**Despite macro weakness, CP’s volume declined just 2% in 2015**
- Most freight types were up or down modestly
  - Canadian commodities performed well, aided by their low-cost position and a weakening Canadian Dollar
  - Portions of CP’s business are not overly sensitive to macro (i.e., intermodal)
- Material declines were seen in just a few categories: US Grain (-9%), Crude (-17%), and Metals, Minerals, and Consumer Products (-14%)

**CP remains a high-quality, infrastructure asset with strong pricing power**
CP: Another Year of Great Progress

- CP’s remarkable transformation continued at an accelerated pace in 2015
  - Operating Ratio ("OR") of 61% improved 370bps
    - Approaching four-year OR target in first year
    - OR result is second-best in industry
  - CP repurchased ~8% of its shares at $203 CAD per share, a discount to CP’s intrinsic value
  - EPS growth of 19% despite muted top-line growth of 2%

- In November, CP revealed its offer for Norfolk Southern
  - Offer would create meaningful value for both CP and NS shareholders while improving the North American rail network and enhancing service to customers
  - Announced US$1.8bn of operational efficiencies and synergies

Despite CP’s continued progress on its operational efficiency, its efforts were mostly overshadowed by its slowing top-line growth and a weakening macroeconomic environment
CP Remains an Attractive Investment

Recent macroeconomic concerns have caused CP’s shares to trade at a substantial discount to their intrinsic value

- 2016 guidance calls for an operating ratio below 59% and double-digit EPS growth
  - Tailwinds to EPS growth from a lower share count, pensions, and f/x

- CP is right-sizing its network to the currently tepid demand environment, which management has stated will improve results meaningfully:
  - Margins should be 200-300 bps higher at current volume levels
  - Annual capital expenditures will be $400mm lower than CP’s original plan

- Long-term potential remains significant under a superlative management team; management has highlighted a potential operating ratio of 56-57%
  - Note that declines in fuel prices, which are passed through to customers via a fuel surcharge, raise the operating ratio potential by ~350-400 bps
  - Pension expense is an incremental tailwind of ~180bps

- Potential for a value-enhancing merger
The total return for CP shares was -20% in 2015

Note: The performance of CP's share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
CP: Share Price Performance Since Inception

CP stock increased 206% from our average cost to January 22, 2016

Stock price performance of CP from 9/22/2011 to 1/22/2016 (CAD)

- 10/2/14: Analyst Day details new four-year targets:
  - 10.5% revenue CAGR
  - Operating ratio of 58-63%
  - EPS of $17, before further buybacks
- 10/24/13: Pershing Square sale of 6 million shares
- 1/22/15: Q4 earnings call:
  - Record 59.8% OR
  - Guidance: ‘15 EPS growth of >25%
- 1/22/16: CP stock increased 206% from our average cost to January 22, 2016

- 5/21/12: All seven Pershing Square nominees elected to Board with 90% of the vote
- 12/4/12: CP Analyst Day details mid-30s margin target by ‘16
- 10/28/11: Pershing Square 13D Filed
- 2/4/13: Keith Creel named Pres. & COO
- 4/28/14: Pershing Square sale of 3 million shares
- 6/29/12: Hunter Harrison named CEO
- 11/13/15: CP’s engages in discussions with Norfolk Southern
- 12/8/15: CP reveals enhanced offer for NS, including proposal of trust structure
- 10/23/13: CP announces strong earnings results while management emphasizes that 65% OR target (35% EBIT margin) is expected by 2014 (two years ahead of four-year timeline)

Note: The performance of CP’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
Restaurant Brands International

Franchised business model is a capital-light, high-growth annuity

- Brand royalty franchise fees (4-5% of unit sales) generate high margins
- Significant unit growth opportunity requires little capital
- Same-store sales are relatively insulated from economic cycles

Control shareholder 3G is ideal operating partner and sponsor

- Installed excellent management team
- Created unique and impactful culture, compensation system, and business processes

Current economic environment is favorable to Restaurant Brands

- Customers have more disposable income and drive more when gas prices are low
QSR’s intrinsic value meaningfully increased in 2015, despite substantial headwinds from strengthening USD.

Strong financial performance in 2015: ~20% EBITDA growth before FX

- Impressive SSS growth at both Burger King (~6%) and Tim Hortons (+5%)
  - Continued progress on Burger King US turnaround (SSS +7%)
- Significantly reduced Tim Hortons expenses and capex
  - Overhead costs reduced by more than 40%
- Maintained high level of net unit growth (5%) at both Burger King and Tim Hortons
- Strengthening of the USD has materially reduced reported financial results
  - FX reduced reported EBITDA growth ~13%

We have taken advantage of recent price declines to add to our position and believe QSR remains a compelling long-term investment.

Note: Financial results for 2015 represent YTD results for the nine months ended 9/30/15.
The total return for Restaurant Brands International shares was -3% in 2015.

Note: The performance of Restaurant Brands International’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds. Source: CapIQ.
Restaurant Brands International stock has increased 123% from our average cost since it merged with Justice Holdings.

Note: The performance of Restaurant Brands International’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds. Share price performance based on close price of Burger King when-issued shares on 6/19/2012.

Source: CapIQ.
Howard Hughes Corporation

- HHC was created by Pershing Square
  - Formed so that certain GGP assets, whose full value would not be realized in a REIT, could receive recognition in the public markets and appropriate management attention
- Comprised of development assets, master planned communities, and income-producing properties with significant upside potential
- In a short period of time, management has designed and launched development and/or monetization plans for each asset
- Residential land holdings and commercial investments within these communities make HHC well positioned to benefit from a housing recovery

We believe that HHC trades at a substantial discount to the value of its assets
HHC continued to enhance the value of its existing assets in 2015

- Significant growth in NOI provides HHC with an increasing stream of recurring, high-multiple cash flows
  - Run-rate NOI increased from ~$47m to ~$180m since 2010

- Strong growth of condo sales revenue and pre-sales at condominium projects in Ward Village

- Declining residential acreage sales at the Woodlands (Houston) MPC

- Strong land sales at Summerlin (Las Vegas) MPC

Recent share price declines reflect concerns about the impact of low oil prices on HHC’s asset value, particularly in Houston

- Substantial majority of HHC’s business and asset value is outside of Houston
  - Nearly all NOI and development assets
  - More than 50% of remaining MPC acres

- HHC expects to sell out remaining MPC land in Houston over many years, so a temporary decline in oil prices will not have a large negative impact on value even if it depresses near-term revenue
The total return for Howard Hughes Corporation shares was -13% in 2015

Note: The performance of HHC’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
Since the spinoff from GGP in November 2010, the Howard Hughes Corporation stock has increased 165%.
2015 was a challenging year for Platform

- **Mixed performance in underlying business results**
  - Double-digit underlying EBITDA growth at MacDermid
  - Slight underlying EBITDA growth in Ag before cost synergies
  - Solid execution of cost synergies in Ag
  - Reduction in distributor inventories will pressure Ag Q4 results

- **Strengthening USD significantly reduced reported results**
  - Adverse FX reduced reported EBITDA growth ~20%

- **Departure of CEO (Dan Leever) and President and Ag CEO (Wayne Hewett)**

- **Multiple reductions to initial 2015 EBITDA guidance**
  - 5% reduction in August due to FX
  - 12% additional reduction in October due to FX and decline in Ag distributor inventories

- **Financial leverage (~6x) currently elevated relative to long-term target (4.5x)**
  - Negative FX impact reduced EBITDA significantly more than debt
  - Alent acquisition financed with debt to avoid dilutive equity issuance

*Note: Financial results for 2015 represent YTD results for the nine months ended 9/30/15.*
Platform Specialty Products Corporation

Platform is working to address the challenges it faced in 2015

- Platform’s current collection of businesses benefit from long-term secular growth trends and have favorable competitive positions

- New CEO and new Ag President are seasoned executives with the appropriate skills to enhance business performance
  - CEO Rakesh Sachdev, former CEO of Sigma Aldrich
  - Ag President Diego Casanello, former Ag executive at BASF

- Recent acquisition of Alent provides opportunity for significant cost and revenue synergies

- We expect Chairman Martin Franklin will further increase his involvement at Platform after the Jarden sale closes
The total return for Platform shares was -45% in 2015.
Platform: Share Price Performance Since Inception

Since the IPO on the London Stock Exchange in May 2013, Platform stock has decreased 22%.

Note: The performance of Platform's share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.

Stock price performance of Platform from 5/16/2013 to 1/22/2016

- 5/17/13: Pershing Square purchases 25m PAH shares at $10
- 10/3/14: Pershing Square purchases 9.4m additional PAH shares at $25.59 increasing average cost to $13.63

Note: The performance of Platform's share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.
Source: Bloomberg.
Nomad Foods (NOMD)

- On June 1, 2015, Pershing Square invested $350mm in a private placement of Nomad shares at $10.50 in conjunction with Nomad’s acquisition of Iglo Group
  - Pershing Square’s Brian Welch joined the Board of Nomad

- Nomad purchased Iglo, Europe’s leading frozen food business, for €2.6bn or 8.5x LTM EBITDA

- In August, Nomad agreed to purchase the highly complimentary non-UK assets of Findus for ~£500mm or 6x EBITDA post-synergies

- Nomad’s acquisitions of Iglo and Findus give it the leading branded frozen foods business in Europe, 2.5x the next largest competitor
  - Leading positions in UK, Italy, Germany, France, Spain, and Nordic region
  - Stable, high-margin, strong cash-flow generation with low capex and cash taxes
  - LTM PF: revenue of €2.1bn, €400mm EBITDA, €1.23 EPS ($1.35)

- A consolidator in the global packaged food sector
  - Large, fragmented packaged foods industry
  - Nomad’s territorial tax domicile will be valuable if it acquires international assets
NOMD stock has increased 12% from our average cost to YE 2015, and decreased 14% to January 22, 2016.

Storm price performance of NOMD from 1/1/2015 to 1/22/2016

8/27/15: Q2 results:
- Revenue decline of 4%; Easter distorted comp; 1H revenues -2%
- EBITDA flat for first half

8/13/15: Nomad announces agreement to acquire non-UK assets of Findus

6/1/15: Pershing Square invests $350mm in private placement of Nomad shares at $10.50 per share

6/23/15: Nomad shares officially resume trading on LSE under ticker NHL

6/1/15: Nomad closes Iglo transaction

4/20/15: Nomad announces acquisition of Iglo

1/12/16: Nomad converts listing from LSE to NYSE; begins trading under ticker NOMD

11/2/15: Nomad closes Findus transaction

11/16/15: Q3 results:
- Revenue down 8%; plan in place to fix execution issues
- EBITDA down 13.6%, partially on tough comparison, margins of 20% on target
- Increased synergy guidance on Findus transaction €10mm to €35-40mm

8/27/15: Q2 results:
- Revenue decline of 4%; Easter distorted comp; 1H revenues -2%
- EBITDA flat for first half

Note: The performance of Nomad Food’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

Source: Bloomberg.
Fannie Mae & Freddie Mac (GSEs)

Fannie and Freddie continued to make positive progress in 2015

- **Underlying earnings in core guarantee business continue to improve**
  - Increase in g-fee rate and lower credit losses
  - Reported results volatile due to non-cash accounting charges on derivatives used to hedge liquidating investment portfolio

- **Consensus is emerging that the GSEs are irreplaceable**
  - Lack of success in attracting private capital to the mortgage market
  - Recent publications from industry trade groups, policy analysts and general news media increasingly recommend maintaining the GSEs

- **Favorable developments with shareholder litigation**
  - Perry appeal from D.C. District Court received strong amici briefs, including from the former Chairman of the FDIC and former Fannie Mae CFO
  - Fairholme discovery in the Federal Court of Claims has uncovered evidence that contradicts the government’s stated rationale for the Net Worth Sweep
  - New lawsuit in Delaware Supreme Court from Chief Justice challenges legality of 3rd Amendment under Delaware law
Amendment prevents Treasury from selling or liquidating its $189bn preferred stock for two years except with Congressional approval

Market is likely misinterpreting the amendment as a precursor to a wind down of the GSEs

Amendment doesn’t present a meaningful obstacle to recapitalization and positive reform of the GSEs
- Only temporary limitation (expires in two years)
- Doesn’t prevent the GSEs from exiting conservatorship or raising external capital
- Doesn’t prevent Treasury from converting its preferred into common equity

Fannie and Freddie present a compelling risk-reward that offers the opportunity to make a large multiple of invested capital and is sized appropriately to limit downside risk to the portfolio
The total return for Fannie Mae and Freddie Mac shares was -20% and -21%, respectively, in 2015.
Since we began accumulating our positions in October 2013, Fannie Mae and Freddie Mac stock prices have decreased 37% and 35%, respectively, from our average cost.

Note: The performance of Fannie Mae and Freddie Mac’s share price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

Source: CapIQ.
Herbalife: It’s a Pyramid Scheme

All facts continue to confirm that Herbalife is a pyramid scheme

- Recently disclosed HLF video emphasizes recruiting and undermines the existence of retail sales
  - CEO Michael Johnson: “It’s the recruiting, meaning bringing new distributors into our company, which is the most vital part of our bloodstream. We bring new distributors in – we grow. It’s that simple. It’s that simple. And the company has built its whole reputation, its whole life, on recruiting.”

- Regulatory investigations ongoing
  - Herbalife has not changed its disclosure about the Department of Justice seeking information from the Company, certain of its Members and others about its business practices
  - In its latest 10Q, HLF’s total expenses for defending itself were $11.2 million in the quarter. Expenses related to “responding to governmental inquiries” increased from $5.8M in Q2 to ~$7.6M in Q3.

- Still No Proof of Retail Sales
  - Through 9/30/15, HLF had spent ~$101 million defending itself, but still refuses to collect retail sales information

Sources: Herbalife financial statements.
1: We believe this clip was taken from a longer video from Herbalife’s 2005 global management retreat, previously reported on by the press.
Herbalife: It’s a Pyramid Scheme

- **Vemma Complaint provides a potential road-map for Herbalife**
  - Herbalife could not survive if the courts applied the same restrictions to Herbalife which they have imposed upon Vemma. Pershing Square has published a detailed side-by-side comparison on our website – FactsAboutHerbalife.com – showing that Vemma and Herbalife are substantially similar.

- **State action by New York Senator Jeff Klein ramps up pressure on Herbalife**
  - New York State Senator Jeff Klein, in conjunction with Public Advocate Letitia James and Make The Road New York, released a highly critical report on Herbalife\(^1\) which concludes that Herbalife distributors are “running an illegal pyramid scheme” and proposes New York State legislation that would amend the New York State General Business Law.

---

\(^1\): The report, titled "The American Scheme: Herbalife's Pyramid Shake'down" is available on Sen. Klein's website.
Recent Financial Results Have Been Weak

Financial results inflected in 2015; 2016 doesn’t look much better

- Revenue declined low-double-digits 2015’YTD as weak organic growth was met with substantial FX headwinds. China was – and continues to be – the single bright spot in Herbalife’s financial performance
  
  - Local currency net sales\(^1\) increased 1.2% while reported sales declined 11.9% for the nine-month period ended September 30, 2015. Excluding China, local currency net sales declined 3.2%.
  
  - Management has guided to mid-single-digit 2016 revenue growth but negative adjusted EPS growth\(^2\); the U.S. Dollar has continued to strengthen since guidance was issued.

- HLF’s 2016 EPS guidance of $4.35 - $4.75 compares to Wall Street projections in mid-2013 of $7.00+ in 2016 earnings.

- HLF continues to point to “changes to the business model”\(^3\) as the reason for a “temporary reset”\(^4\).

---

Source: Herbalife Form 10-Q.

1. Excluding the impact of Venezuela’s Bolivar denominated net sales.

2. Based on the median of the range for Adjusted Diluted EPS of $4.35-$4.75.

3. Q3 2014 Earnings Call.

4. Id.
The Pyramid is No Longer Growing...

Slowing new gross member adds, coupled with constant churn, has caused the total member base to flatline

- The pyramid is no longer growing

- Gross Members additions are poised to decline in 2015

Source: Herbalife financial statements. Note: Full year 2015 Average Active Sales Leaders based on a proprietary forecast for Q4 consistent with year-to-date trends. Full year 2015 Gross New Members based on YTD results annualized.
...Driven by Underlying Operational Drivers

Slowing growth in new Sales Leaders is weighing on Herbalife’s ability to recruit new members

- Growth in Average Active Sales Leaders has slowed meaningfully in recent years

- Additionally, Sales Leaders are less productive at recruiting new members

Source: Herbalife financial statements.
Note: Full year 2015 Average Active Sales Leaders based on a proprietary forecast for Q4 consistent with year to date trends. Full year 2015 Gross New Members based on YTD results annualized.
Volume Growth is Negative

An average Herbalife recruit today purchase fewer volume points per year, further weighing on consolidated volume growth

- New Members are Increasingly Less Valuable
- Volume Growth is Negative

Source: Herbalife financial statements.
Note: Full year 2015 Volume Points based on YTD results annualized.
**Herbalife: Recent Events**

Despite weak operating performance, robust multiple expansion drove significant share price appreciation in 2015

*Note: The performance of HLF's stock price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.*

*Source: Bloomberg.*
From the inception of our short position on May 1, 2012, HLF stock has increased 3%* from our average cost.

Note: The performance of HLF's stock price is provided for illustrative purposes only and is not an indication of future returns of the Pershing Square funds.

*Return of 3% includes dividends amounting to $2.40 since the inception of our position.

Source: Bloomberg.
Exited Positions
Position Exited in 2015
The total return for Allergan shares was 89%* from our average cost basis prior to the position being made public, to the close of the transaction on March 17, 2015.

*The performance of AGN’s stock price does not reflect Pershing Square’s hedges or Valeant’s profit share which would give a lower effective closing price.

Source: Bloomberg.
Business & Organizational Update
Organizational Update

Note: New Hires

Note: Operational Leadership Group Member
## Personnel Updates in 2015

### Legal & Compliance Additions

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Joined</th>
<th>Law Firm</th>
<th>Education</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Fraidin</td>
<td>Vice Chairman</td>
<td>Joined Pershing Square in February 2015</td>
<td>Kirkland &amp; Ellis LLP</td>
<td>J.D., Columbia University Law School, B.A., Tufts University</td>
</tr>
<tr>
<td>Dan Carpenter</td>
<td>Assistant Compliance Officer</td>
<td>Joined Pershing Square in February 2015</td>
<td>Willkie Farr &amp; Gallagher LLP</td>
<td>J.D., Georgetown University Law Center, M.B.A., Simon Graduate School of Business Administration, B.S., Nyack College</td>
</tr>
<tr>
<td>Tina Chan</td>
<td>Assistant Compliance Officer</td>
<td>Joined Pershing Square in September 2015</td>
<td>Willkie Farr &amp; Gallagher LLP</td>
<td>J.D., Harvard Law School, B.A., Cornell University</td>
</tr>
</tbody>
</table>

### Legal & Compliance Departure

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Pershing Square Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Katzovicz</td>
<td>Chief Legal Officer</td>
<td>June 2006 – February 2015</td>
</tr>
</tbody>
</table>
# Personnel Updates in 2015 (continued)

## Communications Addition

**Fran McGill**
- **Communications Associate**
- **Joined Pershing Square in April 2015**
- Rubenstein Associates
- B.S., Syracuse University

## Finance and Accounting Addition

**Louisa Bender**
- **Assistant Controller/Management Co.**
- **Joined Pershing Square in May 2015**
- PricewaterhouseCoopers
- M.S. and B.S., University at Albany, School of Business

## Technology Addition

**Marty Kahn**
- **Application Support Specialist**
- **Joined Pershing Square in June 2015**
- Carlson Capital
- M.S., Pace University
- B.S., University at Albany, SUNY
Personnel Updates in 2016

**Investment Team Departure**

- **Paul Hilal**
  - Investment Team Analyst

**Finance and Accounting Departure**

- **Priti Jajoo**
  - Controller
Additional Disclaimers and Notes to Performance Results

Presentation of Performance Results and Other Data
The performance results of PSH and Pershing Square, L.P., the Pershing Square fund with the longest performance track record, included in this presentation are presented on a gross and net-of-fees basis. Gross and net performance include the reinvestment of all dividends, interest, and capital gains, and reflect the deduction of, among other things, brokerage commissions and administrative expenses. Net performance reflects the deduction of management fees and accrued management fees/allocation and reflects the deduction of, among other things, brokerage commissions and administrative expenses. The net returns for Pershing Square, L.P. set out in this document do not reflect the different fee arrangements in 2003 and 2004. In addition, pursuant to a separate agreement, in 2004 the sole unaffiliated limited partner paid $40,000 for overhead expenses in connection with services provided unrelated to Pershing Square, L.P., which have not been taken into account in determining Pershing Square, L.P.'s net returns. To the extent such overhead expenses had been included in fund expenses, net returns would have been lower.

The market index shown in this presentation, the S&P 500, has been selected for purposes of comparing the performance of an investment in the Pershing Square funds with a well-known, broad-based equity benchmark. The statistical data regarding the index has been obtained from Bloomberg and the returns are calculated assuming all dividends are reinvested. The index is not subject to any of the fees or expenses to which the Pershing Square funds are subject. The funds in which the performance is being measured are not restricted to investing in those securities which comprise the index. The returns attributable to the performance of the Pershing Square funds may or may not correlate to the index and it should not be considered a proxy for the index. The volatility of an index may materially differ from the performance of the Pershing Square funds' portfolio. The S&P 500 is comprised of a representative sample of 500 large-cap companies. The index is an unmanaged, float-weighted index with each stock's weight in the index in proportion to its float, as determined by Standard & Poor's. The S&P 500 index is proprietary to and is calculated, distributed and marketed by S&P Opco, LLC (a subsidiary of S&P Dow Jones Indices LLC), its affiliates and/or its licensors and has been licensed for use. S&P® and S&P 500®, among other famous marks, are registered trademarks of Standard & Poor's Financial Services LLC. © 2015 S&P Dow Jones Indices LLC, its affiliates and/or its licensors. All rights reserved.

Average cost basis is determined using a methodology that takes into account not only the cost of outright purchases of stock (typically over a period of time) but also a per share cost of the shares underlying certain derivative instruments acquired by Pershing Square to build a long position. "Average Cost" reflects the average cost of the position that has been built over time as of the "Announcement Date" which is the date the position was first made public.

Average cost basis for long positions has been calculated based on the following methodology:
(a) the cost of outright purchase of shares of common stock is the price paid for the shares on the date of acquisition divided by the number of shares purchased;
(b) the cost of an equity swap is the price of the underlying share on the date of acquisition divided by the number of shares underlying the call options;
(c) the cost of an equity swap is the reference price of the forward on the date of acquisition divided by the number of shares underlying the forward options;
(d) the cost of options that were in the money at the time of announcement (except when otherwise noted) is the option price plus the strike price less any rebate the Pershing Square funds would receive upon exercise divided by the number of shares underlying the call options;
(e) call options that are out of the money at the time of announcement are disregarded for purposes of the calculation (i.e., the cost of the options acquired are not included in the numerator of the calculation and the underlying shares are not included in the denominator of the calculation);
(f) the cost of the shares acquired pursuant to put options sold by the Pershing Square funds, where the underlying stock was put to the Pershing Square funds prior to the time of announcement, is the (i) strike price of the put options paid when the shares were put to the Pershing Square funds less the premium received by the Pershing Square funds when the put was sold by (ii) the number of shares upon execution of the put option and (iii) premium received from put option written by the Pershing Square funds where the underlying stock was not put to the Pershing Square funds, and the option was out-of-the-money at the time of announcement is included in the numerator of the calculation

With respect to APD, "average cost" accounts for positions in both the Pershing Square funds and the PS V, LP and PS V International, Ltd., co-investment vehicles formed to invest in the securities of (or otherwise seek to be exposed to the value of securities issued by) APD.

With respect to MDLZ, "average cost" does not account for the unwinds of certain of the equity forwards and subsequent purchases of call options on July 29, 2015 and August 5, 2015 (see trading exhibit in our August 6, 2015 10-Q filing).

In relation to Herbalife, the average basis of the short position established by Pershing Square has been calculated based on (i) the proceeds received from the shares sold short divided by (ii) the number of such shares before announcement of the transaction.

Past performance is not necessarily indicative of future results. All investments involve the possibility of profit and the risk of loss, including the loss of principal. This presentation does not constitute a recommendation, an offer to sell or a solicitation of an offer to purchase any security or investment product. Nothing contained herein constitutes an investment, legal, tax or other advice nor is it to be relied on in making an investment or other decision. All information is current as of the date hereof and is subject to change in the future.

Forward-looking Statements
This presentation also contains forward-looking statements, which reflect Pershing Square's views. These forward-looking statements can be identified by reference to words such as “believe”, “expect”, “potential”, “continue”, “may”, “will”, “should”, “seek”, “approximately”, “predict”, “intend”, “plan”, “estimate”, “anticipate” or other comparable words. These forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be certain factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Should any assumptions underlying the forward-looking statements contained herein prove to be incorrect, the actual outcome or results may differ materially from outcomes or results projected in these statements. None of the Pershing Square funds, Pershing Square or any of their respective affiliates undertakes any obligation to update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law or regulation.
Additional Disclaimers and Notes to Performance Results

**Risk Factors**

Investors in PSH may lose all, or substantially all, of their investment in PSH. Any person acquiring shares in PSH must be able to bear the risks involved. These include, among other things, the following:

- PSH is exposed to a concentration of investments, which could exacerbate volatility and investment risk;
- Activist investment strategies may not be successful and may result in significant costs and expenses;
- Pershing Square may fail to identify suitable investment opportunities. In addition, the due diligence performed by Pershing Square before investing may not reveal all relevant facts in connection with an investment;
- While Pershing Square may use litigation in pursuit of activist investment strategies, Pershing Square itself and PSH may be the subject of litigation or regulatory investigation;
- Pershing Square may participate substantially in the affairs of portfolio companies, which may result in PSH’s inability to purchase or sell the securities of such companies;
- PSH may invest in derivative instruments or maintain positions that carry particular risks. Short selling exposes PSH to the risk of theoretically unlimited losses;
- PSH’s non-U.S. currency investments may be affected by fluctuations in currency exchange rates;
- Adverse changes affecting the global financial markets and economy may have a material negative impact on the performance of PSH’s investments;
- Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect PSH’s business, investments and results of operations;
- Pershing Square is dependent on William A. Ackman;
- PS Holdings Independent Voting Company Limited controls a majority of the voting power of all of PSH’s shares;
- PSH shares may trade at a discount to NAV and their price may fluctuate significantly and potential investors could lose all or part of their investment;
- The ability of potential investors to transfer their PSH shares may be limited by the impact on the liquidity of the PSH shares resulting from restrictions imposed by ERISA and similar regulations, as well as a 4.75 per cent. ownership limit;
- PSH is exposed to changes in tax laws or regulations, or their interpretation; and
- PSH may invest in United States real property holding corporations which could cause PSH to be subject to tax under the United States Foreign Investment in Real Property Tax Act.